Replies to post #243540 on NorthWest Biotherapeutics Inc (NWBO)

[Barunuuk]

Correct me if I am wrong, (and I dont mind being wrong), but is Yescarta, or any other Cart-T product approved to be the "Primary Treatment"? I dont believe so.

And I was speaking on DCVax-L specifically, which is GBM focused. Now, I dont mind saying that KITE and JUNO may be or have been further along, but I will say that not by much, and definitely not enough to warrant 100 times the market cap size. My point was that NWBO is on their heels if not right in line with them competitively (if they have positive results of course), and yet their market cap is 0.1% of theirs from 1 - 2 years ago.

[Barunuuk]

Put it this way.... if DCVax-L is approved here in the next year or so, NWBO jumbs right into the mix, and surely becomes a considerable threat to both KITE (Gilead) & JUNO (Celgene). All my point was that NWBO should retain a much larger market cap then it does, even if it is hugely risky.